Abstract: Bi-directional communications system in a CATV network utilizing cell-based Asynchronous Transfer Mode (ATM) transmissions. Packet data existing in any one of several different formats are first converted into ATM cells by a headend controller. Individual cells are then assigned a virtual connection by the headend controller. Based on the virtual connection, the cells can be prioritized and routed to their intended destinations. The cells are transmitted in a shared radio frequency spectrum over a standard cable TV network. A subscriber terminal unit demodulates the received RF signal and processes the cells for use in a computer. Likewise, computers may transmit packet data to their respective subscriber terminal units which are sent to the headend controller over the same CATV network.

Abstract: A process and implementing computer system in which an arbitration circuit is comprised of a plurality of state machines 301, 303 and 305 which combine to receive various system timing signals and provide a data bus grant signal effective to enable data streaming of sequential data blocks of information from an L2 cache memory 109 without intervening wait states between the data blocks.

Abstract: This invention relates to apparatus and methods for fabricating a web or consolidating web precursor material in fabricating a web. The invention comprises ultrasonic bonding apparatus including an anvil roll receiving web materials thereon and receiving first and second rotary ultrasonic horns. The rotary ultrasonic horns, in combination with the anvil roll, ultrasonically bond segments of e.g. first and second webs to each other. Third and fourth rotary ultrasonic horns spaced about the circumference of the anvil roll, in combination with the anvil roll, ultrasonically bond other segments of the webs to each other. The full widths of the webs can be ultrasonically bonded using the rotary ultrasonic horns. An outer surface of the anvil roll preferably carries a bonding pattern defining the locations where bonding of the webs occurs. Additional e.g. third and fourth webs can be bonded by the ultrasonic bonding apparatus.

Abstract: A process and implementing system is provided for conducting a memory test for isolating and identifying failed cache memory modules in a memory subsystem of a computer system. The methodology initially selects 303 a block of memory which is twice the size of the cache 105 being tested. The cache 105 is then disabled 305 and a first test is performed 307 on the selected block of to isolate byte addresses of individual bit failures. If bit failures are detected 308, the appropriate byte address is mapped 310 and the test is ended 321. If no bit errors are detected in the first test, the cache is enabled 309 and a second test is performed and the block is tested 311 for failures. Any detected failures are assumed to be cache failures and the appropriate byte address is mapped 315. The cache is again disabled 317. An appropriate message is then displayed 319 to indicate the results of the testing.

Abstract: A computer system and arbitrator prevent a livelock condition from occurring between a host bus bridge and a PCI bridge, where the host bus bridge and PCI bridge conform to the specification delineated in the PCI-to-PCI Bridge Architecture Specification 1.0 and PCI Local Bus Specification 2.0. The system includes an arbitrator for masking from the PCI bridge a request (REQ.sub.--) generated by a device on a second bus. The arbitrator requests that the host bus bridge flush all existing I/O requests (FLUSHREQ.sub.--) and postpone any future I/O requests from a central processing unit. The third step includes, in response to a notification from the host bus bridge that all I/O requests have been flushed and that any future I/O requests from the central processing unit will be postponed (MEMACK.sub.--), the arbitrator unmasks the request to the PCI bridge (GREQ.sub.--). In response to unmasking the request to the PCI bridge, the PCI bridge grants control of the second bus to the device (GNT.sub.--).

Abstract: A method prevents a livelock condition from occurring between a host bus bridge (e.g., memory controller) and a PCI bus bridge, where the host bus bridge and PCI bus bridge conform to the specification delineated in the PCI-to-PCI Bridge Architecture Specification 1.0 and PCI Local Bus Specification 2.0. The method includes the first step of masking from the PCI bridge a request generated by a device on a second bus. The second step includes requesting that the host bus bridge flush all existing I/O requests and postpone any future I/O requests from a central processing unit. The third step includes, in response to a notification from the host bus bridge that all I/O requests have been flushed and that any future I/O requests from the central processing unit will be postponed, unmasking the request to the PCI bridge. The fourth step includes, in response to unmasking the request to the PCI bus bridge, granting access of the second bus from the PCI bus bridge to the device.

Abstract: A method prevents a livelock condition from occurring between a host bus bridge and a PCI bridge, where the host bus bridge and PCI bridge conform to the specification delineated in the PCI-to-PCI Bridge Architecture Specification 1.0 and PCI Local Bus Specification 2.0. The method includes the first step of in response to at least first and second requests being substantially simultaneously received from at least first and second peripherals, determining if a state of a state machine corresponds to an assigned order of either the first peripheral or the second peripheral. The second step includes if the state does not correspond to the assigned order of the first peripheral or the second peripheral, advancing the state and repeating the first step until the state corresponds to one of the first or second peripherals. The third step includes if the state corresponds to the assigned order of either the first or second peripheral, determining if the selected request targets system memory.

Abstract: A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. The compounds are useful in treating inflammation, and particularly conditions that involve neutrophil influx; they are also useful in inhibiting gastric ulcer formation.

Abstract: In one variant, the invention provides a method of enhancing the activity of phagocytes including macrophages, and in a further variant, a method of modulating the cellular or humoral immune response to warm blooded animals. The invention also provides a method of reducing the adverse effects of stress in warm blooded animals. This is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M.sub.1 --O--Y, an ethereal monosubstitution of monosaccharide derivatives having the general formula M.sub.2 --O--Y, or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In the first variant, the above substances are administered in an amount effective to enhance the microbicidal activity of phagocytes, including macrophages in a normal to depressed state of activation or macrophages already activated in response to infection.

Abstract: A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. The compounds are useful in treating inflammation, and particularly conditions that involve neutrophil influx; they are also useful in inhibiting peptic ulcer formation.

Abstract: A compound of the formula: ##STR1## wherein E is an ethenyl group of the formula: ##STR2## in which X is H when Y is NO.sub.2 ;Y is H when X is NO.sub.2 ; orX is CN when Y is CNwhich has the capacity to form a crystal in which the molecules are aligned substantially in the same manner giving it non-linear optical properties. The crystalline product is thus adapted for use in devices exhibiting non-linear optical effects.

Abstract: The invention provides a method of therapeutically treating a warm blooded animal afflicted with an autoimmune disease such as rheumatoid arthritis. In one variant, this is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M.sub.1 -O--Y, and/or an ethereal monosubstitution of monosaccharide derivatives having the general formula M.sub.2 -O--Y, and/or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In a preferred variant, a synergistic mixture is used containing one or more of the foregoing compounds as a first ingredient and an additional compatible substance as a second ingredient which is effective to therapeutically treat autoimmune diseases in warm blooded animals. The invention further provides a novel synergistic composition for therapeutically treating warm blooded animals afflicted with an autoimmune disease which consists essentially of the aforementioned first and second ingredients.

Abstract: The invention provides a method of therapeutically treating a warm blooded animal afflicted with an autoimmune disease such as rheumatoid arthritis. In one variant, this is accomplished by administering an ethereally monosubstituted monosaccharide having the general formula M.sub.1 --O--Y, and/or an ethereal monosubstitution of monosaccharide derivatives having the general formula M.sub.2 --O--Y, and/or pharmaceutically acceptable organic acid and inorganic acid salts thereof as defined hereinafter. In a preferred variant, a synergistic mixture is used containing one or more of the foregoing compounds as a first ingredient and an additional compatible substance as a second ingredient which is effective to therapeutically treat autoimmune diseases in warm blooded animals. The invention further provides a novel synergistic composition for therapeutically treating warm blooded animals afflicted with an autoimmune disease which consists essentially of the aforementioned first and second ingredients.

Abstract: Inosiplex has been found to be useful as an anti-inflammatory agent, e.g., to treat rheumatoid arthritis. There is no need to employ known anti-inflammatory agents, e.g., indomethacin or aspirin, with it and, in fact, the anti-inflammatory action of inosiplex is reduced if either of these two drugs are present.

Abstract: Thiuram Sulfides of oxazolidines and thiazolidines are disclosed herein and shown to be useful as non-blooming accelerators in the vulcanization of ethylene-propylene-diene-terpolymers.

Abstract: Thiuram sulfides of oxazolidines and thiazolidines are disclosed herein and shown to be useful as non-blooming accelerators in the vulcanization of ethylene-propylene-diene-terpolymers.

Abstract: The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereally monosubstituted monosaccharide having the general formula S--O--Y, wherein S is the residue of a monosaccharide selected from the group consisting of pentoses, hexoses and heptoses and Y is selected from the group consisting of cyclic monovalent nitrogen containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R.sub.1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R.sub.2 and R.sub.3 are selected from the group consisting of --H, --OH, --SH, halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms. The invention also provides certain novel ethereally monosubstituted monosaccharides, of which 3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucose is an example.

Abstract: The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereal monosubstitution of a monosaccharide derivative having the general formula S--O--Y, wherein S is the residue of the monosaccharide derivative selected from the group consisting of pentoses, hexoses and heptoses as single or polysubstituted acetals, ketals or esters and Y is selected from the group consisting of cyclic monovalent nitrogen-containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R.sub.1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R.sub.2 and R.sub.3 are selected from the group consisting of --H, --OH, --SH, halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms.

Abstract: The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereally monosubstituted monosaccharide having the general formula S--O--Y, wherein S is the residue of a monosaccharide selected from the group consisting of pentoses, hexoses and heptoses and Y is selected from the group consisting of cyclic monovalent nitrogen containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R.sub.1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R.sub.2 and R.sub.3 are selected from the group consisting of --H, --OH, --SH, halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms. The invention also provides certain novel ethereally monosubstituted monosaccharides, of which 3--O--3'-(N',N'-dimethylamino-n-propyl)-D-glucose is an example.

Abstract: The invention provides a novel therapeutic composition comprising a pharmaceutically acceptable carrier containing a therapeutically effective amount of an ethereal monosubstitution of a monosaccharide derivative having the general formula S-O-Y, wherein S is the residue of the monosaccharide derivative selected from the group consisting of pentoses, hexoses and heptoses as single or polysubstituted acetals, ketals or esters and Y is selected from the group consisting of cyclic monovalent nitrogen-containing organic radicals and residua and monovalent organic radicals and residua having the general formula ##STR1## wherein R.sub.1 is a divalent organic radical having a linear carbon chain length of about 1-7 carbon atoms and R.sub.2 and R.sub.3 are selected from the group consisting of --H, --OH, --SH; halogen and monovalent organic radicals and residua having a linear carbon chain length of about 1-7 carbon atoms.